In conclusion, in the present study we demonstrated that the mTOR pathway is characteristically activated in liver tumors associated with metabolic syndrome and NASH, unlike liver tumors with other etiologies (Figure 5). This evidence concerns the gene MTOR and metabolic dysfunction-associated steatohepatitis.